Specific reversal agent for dabigatran & in adult patients treated w/ Pradaxa when rapid reversal of anticoagulant effects of dabigatran is required for emergency surgery/urgent procedures; life-threatening or uncontrolled bleeding.
IV Recommended dose: 5 g (2 x 2.5 g/50 mL) as 2 consecutive infusions over 5-10 min each or as bolus inj. Flush IV line w/ sterile NaCl 9 mg/mL (0.9%) soln prior to & at the end of infusion. Recurrent bleeding/potential life-threatening re-bleeding/2nd emergency surgery/urgent procedure w/ prolonged clotting times Consider administration of 2nd 5 g dose. Restarting antithrombotic therapy: After administration, Pradaxa may be reinitiated after 24 hr; other antithrombotic therapy (eg, LMWH) may be started at any time if patient is clinically stable & adequate hemostasis has been achieved.
View Praxbind overdosage for action to be taken in the event of an overdose.
Special Precautions
Hypersensitivity. Discontinue treatment immediately & initiate appropriate therapy if anaphylactic reaction or other serious allergic reaction occurs. Patients w/ hereditary fructose intolerance. Underlying disease predisposing to thromboembolic events in patients on dabigatran therapy. May cause transient proteinuria. Patients on controlled Na diet. Pregnancy & lactation. Childn <18 yr.
Sign Out
